Transplantation using umbilical cord progenitor cells as the source of the stem cells is increasingly recognized as another form of allogeneic transplantation with curative intent. However, the different patterns of hematopoietic and immunological reconstruction have been described in very few patients. A 20-month-old boy presented with acute leukemia. He received standard AML induction and consolidation therapy, after which he underwent allogeneic transplantation using HLA-matched sibling stem cells obtained from the umbilical cord. The preparative regimen consisted of busulfan and cyclophosphamide. White cell recovery, despite concomitant use of G-CSF, was slow, reminiscent of the engraftment pattern without the use of growth factor. Erythroid recovery was best recorded using fetal cell HbF level. Platelet transfusion independence occurred on day +31. Immunologic reconstitution revealed an early NK cell recovery by 6 weeks and progressive T cell recovery until 3 months, with continued increase in counts thereafter. However, the CD4/CD8 ratio remained low even at 14 months post-transplantation. Recovery of B cells was slower until day +120. Proliferative response was within normal range on day +120. This report describes the unique engraftment pattern following umbilical cord blood transplant and emphasizes the pattern of immunological and hematological reconstitution. Leukemia (2000) 14, 931-934.
Introduction
HLA-matched related allogeneic stem cell transplantation has been used to treat high-risk or recurrent hematological malignancies, marrow failure syndromes, severe congenital immunodeficiency states, and select metabolic disorders. The major limitation of using HLA-matched sibling donors has been the fact that only 25% to 30% of potential recipients have such a donor. 1 Both term and preterm umbilical cord blood (CB) contains a significantly higher number of early and committed progenitor cells compared with adult peripheral blood. 2 The use of either related or unrelated donor umbilical CB for allogeneic stem cell transplantation has a number of advantages. Most important is the ease and safety of collection, availability of the stem cells when needed, the low risk of viral contamination, and the potentially reduced risk of GVHD. Augmentation of the donor pool is another important factor. Since the first successful transplantation of cord blood in a child with severe Fanconi anemia, 3 the number of cord blood transplants reported are increasing. [4] [5] [6] As opposed to the data that have been gathered regarding immunological reconstitution after BMT, the knowledge regarding the kinetics of immune recovery in CBT is sparse. 7 A child with acute leukemia who was transplanted with CB is herein reported, emphasizing the pattern of immunological and hematological reconstitution.
Case report
A 20-month-old boy presented with biphenotypic acute leukemia. He received standard AML induction therapy, as per the BFM protocol, 8 consisting of cytarabine, daunorubicin and etoposide. This was followed by one course of consolidation with prednisone, 6-thioguanine, vincristine, doxorubicin, cytarabine, cyclophosphamide and intrathecal cytarabine, after which he underwent an allogeneic transplantation using HLA-matched sibling stem cells obtained from the umbilical cord. There were 270 ml of CB containing 8 × 10
7 white blood cells (WBC)/kg and 3.7 × 10 7 mononuclear cells/kg. The preparative regimen consisted of busulfan 4 mg/kg orally in divided doses daily for 4 days (total dose 16 mg/kg) and cyclophosphamide 50 mg/kg once daily i.v. for 4 consecutive days (total dose 200 mg/kg). G-CSF 5 g/kg was given from day +1 until neutrophil engraftment. The patient was discharged on day +40 after uneventful hospitalization and remains leukemia-free and well 15 months post-transplantation.
GVHD prophylaxis consisted of cyclosporine A (CsA), starting on day −1 at a dose of 1.5 g/kg i.v. twice daily and subsequently at a dose of 3 mg/kg p.o. twice daily. Methotrexate was given i.v. at a single dose of 15 mg/m 2 on day +1 and in single doses of 10 mg/m 2 on days +3 and +6. CsA was discontinued by day +90. Acyclovir was administered prophylactically at a dose of 500 mg/m 2 three times daily i.v. from day −7, and later p.o. until day +300 after CBT. Immunoglobulins were administered i.v. at a dose of 500 mg/kg once every 2 weeks for the first 90 days after CBT, with the aim of reducing the risk of infection. Hematopoietic and lymphoid engraftment were documented by studying the genetic polymorphism of variable numbers of tandemly repeated short DNA sequences (VNTR). WBC engraftment was defined as the first of 3 consecutive days when polymorphonuclear cells (PMN) were Ͼ0.5 × 10 9 /l and platelet engraftment as the first of 3 consecutive days when the unsupported platelet count was Ͼ50 × 10 9 /l. Quantitation of fetal Hb was based on its resistance to denaturation at alkaline pH (Betke procedure). The presence of HbF in F cells was demonstrated by the Kleihauer-Betke elution procedure. 9 Collection, processing and thawing of CB CB was collected in bags containing 20 ml acid-citratedextrose (ACD) as an anticoagulant. Unmanipulated CB was frozen as whole blood and stored in Gambro-NPBI DF-200-3 containers (NPBI, Amsterdam, The Netherlands) in liquid nitrogen tanks. CB units were thawed in a 37°C bath and promptly infused.
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Isolation of PBMC
Heparinized peripheral blood was drawn from the patient at various times post-transplantation in order to check immunological reconstitution. PBMC were isolated by Ficoll-Hypaque density gradient centrifugation, resuspended in RPMI 1640 medium (GIBCO) supplemented with 2 mM L-glutamine and 5% FCS (RPMI-FCS) and employed on the same day or cryopreserved for later use.
Surface marker analysis
The MoAbs employed in this study included CD4, CD7, CD8, CD16, CD19, CD20 and CD56 (Becton Dickinson, Mountain View, CA, USA). Appropriate isotype-matched controls were included. Phenotypic analyses of cell populations were performed by means of direct immunofluorescence in two-color analyses using directly labeled Abs on a FACSCalibur flow cytometer (Becton Dickinson).
Proliferation assays
PHA (P-form, GIBCO, Paisley, UK), Con A (Pharmacia, Uppsala, Sweden) and OKT3 (anti-CD3; Ortho, Raritan, NJ, USA) activation was obtained by incubating lymphoid cells, seeded in triplicate in round-bottom microwells at a concentration of 1 × 10 6 cells/ml, with PHA (5 g/ml), Con A (10 g/ml) and OKT3 mAb (10 ng/ml), respectively, in a final volume of 0.2 ml of RPMI-FCS. After a 3-day incubation at 37°C in a humidified 5% CO 2 atmosphere, 3 H-TdR incorporation was measured during the last 18 h by a standard procedure.
Results
WBC engraftment with absolute PMN count Ͼ500/l occurred on day +19, and an absolute neutrophil count (ANC) Ͼ1000/l was reached on day +22. Despite concomitant use of G-CSF, WBC recovery was slow -reminiscent of the postallogeneic engraftment pattern without the use of growth factor ( Table 1 ). The last platelet transfusion was given on day +31. Thereafter the platelet count was gradually increased, with platelets Ͼ100 000 l by day +45. Red blood cells (RBC) engraftment was best recorded using measurement of HbF and looking at F cells on blood films (Table 2 ). RBC transfusion independence was reached by day +36, when the HbF was 3.6% and the F cells were 7-8%. HbF levels showed a steady increase until day +113, with subsequent decline until day +421 (2.1%) (Figure 1 ). F cells were not seen at that time. The Table 1 WBC recovery decline was less pronounced than that observed in normal children in the first year of life, where the HbF reaches its normal value by age 6 months. 10 Immunological reconstitution was followed by measuring lymphoid cell subpopulations and mitogen-induced PBMC proliferation (Tables 3 and 4) . Early natural-killer (NK) cell recovery was seen by 6 weeks. The T cells recovered progressively until 3 months, with continued increase in counts up to 1 year. The CD4/CD8 ratio remained low even at 14 months post-transplantation. The proliferative response of T lymphocytes to polyclonal activators (PHA, Con A, anti-CD3) was detectable as early as day +42, with a steady increment afterwards until they were within normal range by day +120. B cell recovery was slow until day +120. Using the VNTR systems apo B and PYN-2, full donor chimerism was demonstrated on day +330. There were no signs of acute or chronic GVHD and no evidence of veno-occlusive disease of the liver, and the patient remains in complete hematological remission.
Discussion
Umbilical CB has been proposed as an alternative source of allogeneic hematopoietic stem cells for transplantation. Among 44 children with acquired or congenital lymphohematopoietic disorders, neuroblastoma, or metabolic diseases who underwent CB transplantation, hematopoietic growth factors had no demonstrable effect on time to neutrophil recovery. 4, 11 For patients who received growth factor and engrafted, the median time to neutrophil recovery was 21 days; for those who did not receive growth factor and engrafted, the median time to neutrophil recovery was 22 days. The time to neutrophil recovery did not correlate with the number of nucleated cells or granulocyte-macrophage colony-forming units infused. However, in another report on outcome among 562 recipients of unrelated cord blood transplantation, 6 the time to myeloid engraftment in patients who reached an absolute neutrophil count of Ͼ500/l, was correlated with the number of leukocytes per kilogram in the placental-blood graft. Gluckman et al 5 summarized 143 cord blood transplantations performed from 1988 to 1996, 78 patients received cord blood from a related donor, and 65 received cord blood from an unrelated donor. The median time needed to reach an absolLeukemia ute neutrophil count of at least 500/l was 30 days (range 8-56). They found that the number of nucleated cells infused per kilogram was a major factor in the recovery of neutrophil counts. Those who received 3.7 × 10 7 or more nucleated cells per kilogram achieved faster engraftment than those who received less. Our patient engrafted on day +19. Despite addition of G-CSF, the kinetics of neutrophil recovery were slow ( Table 1 ). The reason for this sluggish myeloid engraftment could relate to the differentiating capacity of CB cells and their reaction to G-CSF. Recent studies examining the complex regulatory mechanisms associated with GM-CSF mRNA expression and protein production have suggested a significant decrease in post-transcriptional stability in umbilical CB compared with adult PBMC. 12 RBC engraftment was followed by measuring HbF and F cells. The Hb electrophoretic pattern observed in our patient reflects the predominant production of HbF during the early months after CBT. As soon as HbF appeared (2.0-3.6%), there was no need for further blood transfusion. The highest HbF percent was by day +113, and the decline afterwards persisted beyond 1 year following transplantation, possibly due to delayed switch from fetal to adult Hb synthesis. Another possible explanation for the prolonged involvement of F cell clones in erythropoiesis is the state of marrow regeneration after BMT, which involves a rise in HbF. 7 Values observed in allogeneic BMT recipients range between 1% and 7%. 13 Compared with allogeneic BMT the data in the literature regarding immunologic reconstitution following cord blood transplantation is still sparse. There is only one report 7 which described three patients with acute lymphoblastic leukemia, aged 10, 9 and 7 years. The immunological reconstitution of our patient were compared with the results of that study.
NK cells reappear early after BMT and during the first month represent the major lymphoid population.
14 Our patient showed early NK cell recovery by 6 weeks, as has also been described elsewhere. 7 Normalization of the percentage and absolute number of CD8 + T lymphocytes is more rapid than that of CD4 + T lymphocytes. 15 CD8 + T lymphocytes reach normal values 4 months after BMT, whereas significant decreases in CD4 + T lymphocytes persist for the first 6 months after BMT. This results in an inversion of the normal CD4/CD8 ratio, which does not normalize until 6 to 9 months after BMT. Our patient had a persistently low CD4/CD8 ratio even at 14 months after transplantation. The three other patients described 7 showed different CD4/CD8 ratios. The one that received cord blood and marrow cells had a normal CD4/CD8 ratio 12 months post-transplant. The two others received cord blood alone and demonstrated in one patient a CD4/CD8 ratio closer to normal (1.4) at 12 months post-transplant, and a low CD4/CD8 ratio (0.17) in the other patient at 9 months post-transplant.
The recovery of T lymphocyte function following BMT can be assayed in terms of the response to either non-specific stimuli (PHA, anti-CD3) or specific antigenic stimulation (tetanus toxoid, herpes virus Ags). Recipients of non-T cell-depleted marrow show decreased proliferation to stimulation with PHA or anti-CD3 Abs for the first 1 to 2 months after BMT. 16 By 4 to 6 months, proliferative responses to mitogenic stimulation normalize. The proliferative response after allogeneic stimulation of E-rosetted T cells is similar in umbilical CB compared with adult peripheral blood. 17 Others detected a proliferative response of T lymphocytes to polyclonal activators (PHA, Con A, anti-CD3) as early as 1 month after CBT, with fluctuation in the response afterwards. 7 Our patient showed a response to the same activators as early as day +42 after CBT; the response steadily increased with time until it was within normal range on day +120.
The number of B lymphocytes, as determined by either the presence of surface lg or CD20 expression, usually returns to normal levels 1 to 2 months after BMT.
14 CB recipients showed an impressive increase of CD19 B cells starting 2 months after CBT. 7 These lymphocytes also expressed CD20 Ag. This increase was not related to reactivation of EBV. It has been hypothesized that this striking expansion of B cells is due to the absence of long-term memory B cells that usually are found in adult BM, while only immature naive B lymphocytes are found in CB. 7 Newly generated B lymphocytes are necessary for further Ab production. 18 Our patient did not follow this pattern and showed gradual increment in the B cell number, reaching a normal number at 4 months after CBT, with a further increase afterwards.
In conclusion, this patient confirms and adds to the emerging data regarding umbilical CB transplantation. CB as a source of stem cells can lead to engraftment with long-term reconstitution of hematopoietic cells in a patient with acute leukemia. Full immunological recovery may take longer than 1 year, with NK cells appearing first and a gradual increase in T and B cell numbers afterwards. The CD4/CD8 ratio remains low even at 14 months after transplantation. HbF levels and F cells may be useful early markers of erythroid engraftment.
